Citius Pharmaceuticals, Inc.
CTXR
$0.56
-$0.03-5.65%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -9.88% | 9.55% | 4.36% | -5.15% | -16.16% |
| Total Depreciation and Amortization | 1,014.31% | 235.71% | 2.19% | 0.00% | 7.52% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -50.37% | -4.61% | -22.55% | -26.03% | -6.06% |
| Change in Net Operating Assets | -10.64% | -937.35% | 162.52% | 335.91% | 243.71% |
| Cash from Operations | -34.19% | -30.02% | 5.85% | 29.24% | 22.30% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -115.00% | -103.00% | -15.00% | -- | -- |
| Cash from Investing | -115.00% | -103.00% | -15.00% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 137.56% | 209.00% | 134.02% | 11.22% | 32.29% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 95.58% | -- | -- | -218.81% | -218.81% |
| Cash from Financing | 192.96% | 311.33% | 233.95% | 0.32% | 16.05% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 136.41% | 134.40% | 104.31% | 23.09% | 24.07% |